Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LeMaitre VascularLMAT +0.78%100 Return-on-Tangible-Asset is 12.68% as of Jun. 2026, which is 18% below its 10-year median of 15.53. GuruFocus rates LMAT with a GF Score™ of 100/100 and a GF Value™ of $95.26 (Modestly Undervalued). Among 854 Medical Devices & Instruments companies, LeMaitre Vascular ranks better than 88.64% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. LeMaitre Vascular's annualizedNet Income for the quarter that ended in Jun. 2026 was $68.2 Mil. LeMaitre Vascular's average total tangible assets for the quarter that ended in Jun. 2026 was $538.0 Mil. Therefore, LeMaitre Vascular's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 12.68%.
The historical rank and industry rank for LeMaitre Vascular's Return-on-Tangible-Asset or its related term are showing as below:
LMAT'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 11.09 Med: 15.53 Max: 22.52
Current: 12.77
During the past 13 years, LeMaitre Vascular's highest Return-on-Tangible-Asset was 22.52%. The lowest was 11.09%. And the median was 15.53%.
LMAT's Return-on-Tangible-Asset is ranked better than 88.64% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 0.59
vs LMAT: 12.77
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
LeMaitre Vascular Return-on-Tangible-Asset Related Terms
LeMaitre Vascular Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for LeMaitre Vascular's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LMAT vs PLSE, XRAY, ATRC: Return-on-Tangible-Asset Comparison
For the Medical Instruments & Supplies subindustry, LeMaitre Vascular's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LeMaitre Vascular Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, LeMaitre Vascular's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where LeMaitre Vascular's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 12.68% mean?
LeMaitre Vascular (LMAT) has a Return-on-Tangible-Asset of 12.68% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on LeMaitre Vascular and its competitors. This is 18% below median its historical median of 15.53. Over the past decade, LeMaitre Vascular's Return-on-Tangible-Asset has ranged from 11.09 to 22.52. According to the industry distribution chart, LeMaitre Vascular ranks #97 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 11.4%.
Is LeMaitre Vascular's Return-on-Tangible-Asset too high?
LeMaitre Vascular's current Return-on-Tangible-Asset of 12.68% is 18% below median its 10-year median of 15.53. Over the past 10 years, this metric has ranged from a low of 11.09 to a high of 22.52. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.59. LeMaitre Vascular's value of 12.68% is 2049.2% above this industry median. Based on the distribution chart, LeMaitre Vascular ranks #97 out of 854 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, LeMaitre Vascular has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does LeMaitre Vascular's Return-on-Tangible-Asset compare to PLSE and XRAY?
According to the Medical Devices & Instruments industry distribution chart, LeMaitre Vascular ranks #97 out of 854 companies for Return-on-Tangible-Asset. This places LeMaitre Vascular in the top 11% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 0.59. LeMaitre Vascular's value of 12.68% is 2049.2% above this benchmark. Historically, LeMaitre Vascular's own Return-on-Tangible-Asset has ranged from 11.09 to 22.52 over the past decade. While the company's 10-year median is 15.53 vs. the industry median of 0.59, LeMaitre Vascular has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.59, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LeMaitre Vascular's current Return-on-Tangible-Asset of 12.68% is 2049.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on LeMaitre Vascular and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LeMaitre Vascular's current Return-on-Tangible-Asset is 12.68%, which is 18% below median its own 10-year median of 15.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LeMaitre Vascular stock overvalued right now?
Based on GuruFocus' analysis, LeMaitre Vascular (LMAT) is currently considered Modestly Undervalued. The stock's GF Value™ is $95.26, compared to a current price of $81.45 — trading 14.5% below its estimated fair value. The current Return-on-Tangible-Asset is 12.68%, which is 18% below median its 10-year median of 15.53 and 2049.2% above the Medical Devices & Instruments industry median of 0.59. LeMaitre Vascular's overall GF Score™ is 100/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For LeMaitre Vascular (LMAT), the current Return-on-Tangible-Asset is 12.68% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LeMaitre Vascular (LMAT) Overvalued in 2026?
Based on GuruFocus' analysis, LeMaitre Vascular stock appears to be undervalued.
The current stock price of $81.45 is trading 14.5% below its estimated GF Value™ of $95.26.
GuruFocus considers LeMaitre Vascular to be Modestly Undervalued.
Key valuation signals for LMAT:
Return-on-Tangible-Asset: 12.68% (18% below median its 10-year median of 15.53)
GF Value™: $95.26 vs. price of $81.45 (14.5% below fair value)
Industry Position: 2049.2% above the Medical Devices & Instruments median (#97 of 854)
No single metric tells the full story. See the LMAT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.
100GF Score
Get the complete analysis for LMAT
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LMAT has been successfully added to your 
